Brexit Whitepaper No. 4 – What’s Next? – Download It Here
In our 4th Acorn Regulatory Brexit whitepaper entitled ‘What’s Next’ we focus on the results of our extensive Brexit survey. We look at our survey respondents favoured locations for the EMA, the future of the MHRA and much more.
Acorn Regulatory NewsAuditClinical & MedicalPharmaceuticalPharmacovigilancePublicationsQuality Management System
Download ‘Regulatory Intelligence’ from Acorn Regulatory
Our team of regulatory affairs experts is regarded as the thought leader in the sector. They have worked on some of the most challenging and groundbreaking regulatory projects in modern times. They regularly write for specialist periodicals and speak...
Download ‘The Road Ahead’ – Our Latest Brexit Whitepaper
Editor’s Note: ‘The Road Ahead’ whitepaper was first published in January 2017. Much has happened with Brexit since then. You can stay up to date on all of the Acorn Regulatory Brexit content here. Now that the British Prime Minister...
Lancaster House Speech & What It Means for Life Sciences
British Prime Minister Theresa May’s Lancaster House speech was much anticipated by many sectors, including the life sciences sector in the UK and further afield. In this brief PDF we look at the implications of her speech for the life...
Download Our Latest Brexit Whitepaper – Heading for the Exit
Where Next for the European Medicines Agency? In our second Brexit whitepaper, we are looking at the implications of the decision to leave on one of the most ‘mission-critical’ agencies of the EU – the European Medicines Agency. The future...
The Implications of Brexit on the Pharmaceutical, Medical Devices & Clinical Trials Sectors
Acorn Regulatory has published a whitepaper looking at the potential implications of Brexit on a number of healthcare sectors. The document looks at the impact of the UK’s decision to leave the EU on institutions such as the EMA. It also...
By using this website, you agree to our
cookie policy.
Close